Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
43 hedge funds and large institutions have $19.6M invested in Clearside Biomedical in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 10 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
0.42% more ownership
Funds ownership: 1.29% → 1.71% (+0.42%)
9% less funds holding
Funds holding: 47 → 43 (-4)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
15% less capital invested
Capital invested by funds: $23M → $19.6M (-$3.48M)
93% less call options, than puts
Call options by funds: $123K | Put options by funds: $1.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$4.88M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.42M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$800K |
| 4 |
Renaissance Technologies
New York
|
+$750K |
| 5 |
Morgan Stanley
New York
|
+$639K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$443K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$295K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$150K |
| 4 |
PMFA
Plante Moran Financial Advisors
Southfield,
Michigan
|
-$145K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$114K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CP
51
Corbenic Partners
Bethlehem,
Pennsylvania
| – | -$1K | -24 | Closed |
|
52
Wells Fargo
San Francisco,
California
| – | +$629 | +17 | New |
|
CLSD Hedge Fund Activity: Q1 2020 in Review
43 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2020, worth a combined $19.6M — down 15% from $23M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLSD and 9 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 13 added.
The largest buyer was Carmignac Gestion, opening a new position worth an estimated $4.88M. The largest seller was Millennium Management, cutting an estimated $443K.
- 43 institutional investors held Clearside Biomedical (CLSD) as of Q1 2020, down from 47 in Q4 2019.
- Funds reported $19.6M of Clearside Biomedical stock for Q1 2020, down 15% quarter-over-quarter.
- 9 funds opened new Clearside Biomedical positions in Q1 2020 and 10 closed out, a net change of -1 holder.
- The largest Clearside Biomedical buyer in Q1 2020 was Carmignac Gestion, an estimated $4.88M added.
- The largest Clearside Biomedical seller in Q1 2020 was Millennium Management, an estimated $443K sold.
Based on aggregated 13F filings for Q1 2020.